• 1
    Havenaar R, Huis in't Veld JHJ. Probiotics: a general view. In: WoodBJB, ed. The lactic acid bacteria, vol. 1. The lactic acid bacteria in health and disease. London: Chapman & Hall, 1992:20924.
  • 2
    Food and Agriculture Organization of the United Nations and World Health Organization (FAO/WHO). Guidelines for the evaluation of probiotics in food. London/Ontario/Canada: FAO/WHO. Available at: (accessed 1 June 2007).
  • 3
    Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001; 73:3938 [Review].
  • 4
    Pineiro M, Stanton C. Probiotic bacteria: legislative framework − requirements to evidence basis. J Nutr 2007; 137:8503.
  • 5
    Daniel C, Poiret S, Goudercourt D, Dennin V, Leyer G, Pot B. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl Environ Microbiol 2006; 72:5799805.
  • 6
    Von Wright A. Regulating the safety of probiotics − the European approach. Curr Pharm Des 2005; 11:1723 [Review].
  • 7
    Gueimonde M, Salminen S. New methods for selecting and evaluating probiotics. Dig Liver Dis 2006; 38:242S7S.
  • 8
    Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:125664 [Review].
  • 9
    Dunne C, O'Mahony L, Murphy L et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001; 73:38692 [Review].
  • 10
    Huis in't Veld J, Havenaar R, Marteau P. Establishing a scientific basis for probiotic. R&D Trends Biotechnol 1994; 12:68.
  • 11
    Haller D, Colbus H, Gänzle MG, Scherenbacher P, Bode C, Hammes WP. Metabolic and functional properties of lactic acid bacteria in the gastro-intestinal ecosystem: a comparative in vitro study between bacteria of intestinal and fermented food origin. Syst Appl Microbiol 2001; 24:21826.
  • 12
    Ishida Y, Nakamura F, Kanzato H et al. Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial. Biosci Biotechnol Biochem 2005; 69:165260.
  • 13
    Ohno H, Tsunemine S, Isa Y, Shimakawa M, Yamamura H. Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen specific immunoglobulin E production in mice. Biol Pharm Bull 2005; 28:14626.
  • 14
    Gionchetti P, Lammers KM, Rizzello F, Campieri M. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. Gastroenterol Clin North Am 2005; 34:499513 [Review].
  • 15
    Young SL, Simon MA, Baird MA et al. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clin Diagn Lab Immunol 2004; 11:68690.
  • 16
    Niers LE, Timmerman HM, Rijkers GT et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy 2005; 35:14819.
  • 17
    Boyle RJ, Tang ML. The role of probiotics in the management of allergic disease. Clin Exp Allergy 2006; 36:56876 [Review].
  • 18
    Lammers KM, Brigidi P, Vitali B et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 2003; 38:16572.
  • 19
    Pena JA, Versalovic J. Lactobacillus rhamnosus GG decreases TNF α production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 2003; 5:27785.
  • 20
    Matsuguchi T, Takagi A, Matsuzaki T et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol 2003; 10:25966.
  • 21
    Hoarau C, Lagaraine C, Martin L, Velge-Roussel F, Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J Allergy Clin Immunol 2006; 117:696702.
  • 22
    Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996; 64:54035.
  • 23
    Collado MC, Gueimonde M, Hernandez M, Sanz Y, Salminen S. Adhesion of selected Bifidobacterium strains to human intestinal mucus and the role of adhesion in enteropathogen exclusion. J Food Prot 2005; 68:26728.
  • 24
    Kaufmann P, Pfefferkorn A, Teuber M, Meile L. Identification and quantification of Bifidobacterium species isolated from food with genus-specific 16S rRNA-targeted probes by colony hybridization and PCR. Appl Environ Microbiol 1997; 63:126873.
  • 25
    Gueimonde M, Delgado S, Mayo B, Ruas-Madiedo P, Margolles A, De Los Reyes-Gavilan C. Viability and diversity of probiotic Lactobacillus and Bifidobacterium populations included in commercial fermented milks. Food Res Int 2004; 37:83950.
  • 26
    Gackowska L, Michalkiewicz J, Krotkiewski M, Helmin-Basa A, Kubiszewska I, Dzierzanowska D. Combined effect of different lactic acid bacteria strains on the mode of cytokines pattern expression in human peripheral blood mononuclear cells. J Physiol Pharmacol 2006; 57:1321.
  • 27
    Feng CG, Kullberg MC, Jankovic D et al. Transgenic mice expressing human interleukin-10 in the antigen-presenting cell compartment show increased susceptibility to infection with Mycobacterium avium associated with decreased macrophage effector function and apoptosis. Infect Immun 2002; 70:66729.
  • 28
    Balcewicz-Sablinska MK, Gan H, Remold HG. Interleukin 10 produced by macrophages inoculated with Mycobacterium avium attenuates mycobacteria-induced apoptosis by reduction of TNF-alpha activity. J Infect Dis 1999; 180:12307.
  • 29
    Sanz Y, Nadal I, Sánchez E. Probiotics as drugs against human gastrointestinal infections. Recent Patents Anti-infect Drug Discov 2007; 2:14856.
  • 30
    Collado MC, Gueimonde M, Sanz Y, Salminen S. Adhesion properties and competitive pathogen exclusion ability of bifidobacteria with acquired acid resistance. J Food Prot 2006; 69:16759.
  • 31
    Grangette C, Nutten S, Palumbo E et al. Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 2005; 102:103216.
  • 32
    Matsumoto S, Hara T, Hori T et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140:41726.
  • 33
    Timmerman CP, Mattsson E, Martinez-Martinez L et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993; 61:416772.
  • 34
    Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:5208.
  • 35
    Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002; 168:471120.
  • 36
    Takahashi N, Kitazawa H, Iwabuchi N et al. Immunostimulatory oligodeoxynucleotide from Bifidobacterium longum suppresses Th2 immune responses in a murine model. Clin Exp Immunol 2006; 145:1308.
  • 37
    Takahashi N, Kitazawa H, Iwabuchi N et al. Oral administration of an immunostimulatory DNA sequence from Bifidobacterium longum improves Th1/Th2 balance in a murine model. Biosci Biotechnol Biochem 2006; 70:201317.